cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Cagrilintide–semaglutide (CagriSema) versus or in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, study Novo Nordisk's next-gen obesity drug

GrivaMLagoudakiRTouloumiONousiopoulouEKaralisFGeorgiouTet alLong-term effects of enriched environment following neonatal hypoxia-ischemia on behavior, Bdnf and synaptophysin levels in rat hippocampus: effect of combined treatment with G-Csf

Find out if it works and if it's safe

Let's boost your wellness together

These results support development of small molecule NNMT inhibitors as therapeutics to reverse diet-induced obesity and validate NNMT as a viable target to treat obesity and related metabolic conditions

10 ,

Suggested starting points to discuss with your clinician Deficiency without malabsorption: 1,0002,000 mcg oral cyanocobalamin daily until normalized, then weekly or monthly maintenance per labs (AAFP)